Evidence map›Paper›PMID 42850455›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus.

Alessandro Padovani, Mattia Altini, Giuseppe Bellelli, Marco Bozzali, Ovidio Brignoli, Annachiara Cagnin, Antonio Cherubini, Manuele Iannacci, Raffaele Lodi, Giancarlo Logroscino and 6 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alessandro PadovaniDepartment Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Mattia AltiniLocal Health Authority of Modena (AUSL Modena), Modena, Italy.
Giuseppe BellelliSchool of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Marco BozzaliDepartment of Neuroscience, Rita Levi-Montalcini, University of Torino, Turin, Italy.
Ovidio BrignoliItalian College of General Practitioners and Primary Care Professionals (SIMG), Florence, Italy.
Annachiara CagninDepartment of Neuroscience, University of Padova, Padua, Italy.
Antonio CherubiniGeriatric Admission Unit and Research Centre On Aging, IRCCS INRCA, Ancona, Italy.
Manuele IannacciLocal Health Authority of Modena (AUSL Modena), Modena, Italy.
Raffaele LodiFunctional and Molecular Neuroimaging Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy.
Giancarlo LogroscinoCentre for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari 'Aldo Moro', Tricase, Lecce, Italy.
Camillo MarraDepartment of Psychology, Catholic University of the Sacred Heart, Milan, Italy.
Carlo NicoraFondazione Molina Varese, Varese, Italy.
Simone ParrettiIQVIA, Milan, Italy. simone.parretti@iqvia.com.ORCID http://orcid.org/0009-0007-7096-3549
Anna SaccoIQVIA, Milan, Italy.
Patrizia SpadinItalian Alzheimer's Disease Association (AIMA), Milan, Italy.
Mario ZappiaItalian Society of Neurology (SIN), Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) poses a growing clinical and organizational challenge, requiring coordinated, multidisciplinary care models. In Italy, significant regional variability in resources and access to diagnostic services persists, while the implementation of community-based care models, the expanding role of biomarkers, and the advent of disease-modifying therapies (DMTs) further highlight the need for a more coordinated and equitable dementia care network.

objectiveDevelop system-level recommendations to optimise the organisation of AD care delivery in Italy in anticipation of DMTs introduction.

methodsUsing the RAND/UCLA Appropriateness Method, a multidisciplinary panel rated 55 statements across nine domains, evaluating appropriateness in two rounds and priority of implementation in a third round.

resultsConsensus was achieved for all statements, with high appropriateness and priority ratings. The statements outline a regional, network-based model organised across territorial services, Spoke and Hub centres, with formal governance responsible for pathway definition and monitoring. Referral pathways from primary care are based on cognitive and frailty assessment, with non-frail patients referred to Spoke for clinical, neuropsychological and neuroradiological evaluation. Patients potentially eligible for DMTs are referred to Hub centres, where diagnostic confirmation is completed and multidisciplinary teams assess treatment eligibility. When authorised, Hub centres are responsible for DMTs prescription and administration. The statements emphasise the need for standardised neuropsychological and neuroradiological protocols for amyloid-related imaging abnormalities (ARIA) monitoring, alongside the progressive adoption of plasma biomarkers, telemedicine, and structured communication with patients and caregivers.

conclusionThis consensus provides a pragmatic framework to support the reorganisation of AD care in Italy, ensuring that every patient is directed to the most appropriate level of care across a flexible regional network.

Indexed as

Alzheimer DiseaseDelivery of Health CareConsensusHumansItalyAlzheimer’s diseaseCare pathwaysConsensus studyDisease-modifying therapiesHealthcare organizationItaly

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.